FDA accepts NDA for tirabrutinib in relapsed or refractory PCNSL
The filing was supported by results from the phase 2 PROSPECT study, which demonstrated an overall response rate of 67 percent and a
Lymphoma
Aggressive B-Cell Lymphomas
News
Multiple Myeloma
News
FDA approves teclistamab combo in relapsed myeloma
In a phase 3 clinical trial, the combination showed significant improvements in progression-free survival and overall survival compared with the standard of care.
Myeloproliferative Neoplasms
Polycythemia Vera
News
FDA grants priority review to rusfertide in polycythemia vera
Results from the phase 3 VERIFY study supported the filing, showing that the drug improved hematocrit levels and lowered the frequency of required
SOHO UK
Cellular Therapy
Acute Lymphoblastic Leukemia
Aggressive B-Cell Lymphomas
A view from SOHO UK: navigating the challenges and complexity of haematology
While we cannot ignore the wider challenges facing the NHS, the SOHO UK programme highlights the extraordinary pace of progress in haematology. Alongside
Leukemia
Acute Myeloid Leukemia
News
FDA clears IND application for TBS-2025 in AML
The upcoming Phase 2 study will utilize a Simon 2-stage design and focus on patients who have not previously received a menin inhibitor.
Leukemia
Chronic Lymphocytic Leukemia
Lymphoma
Indolent B-Cell Lymphomas
News
FDA approves acalabrutinib plus venetoclax for CLL, SLL
The approval follows results based on the phase 3 AMPLIFY trial, which showed that this fixed-duration combination significantly improved progression-free survival compared to
ASH 2025
Acute Myeloid Leukemia
News
Prof. Charles Craddock, CBE, discusses paradigm trial, transplant advances at ASH 2025
Charles Craddock, CBE, FRCP, FRCPath, professor of hematology-oncology at the University of Birmingham and consultant hematologist at University Hospitals Birmingham, shares ASH 2025
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
News
Assay targeting KMT2A rearrangements in AML now available
Invivoscribe has announced the launch of its newly developed test for leukemia diagnostics, the LeukoStrat® KMT2A + MRD Assay, specifically for patients with
Multiple Myeloma
News
FDA issues draft guidance on MRD, CR endpoints in MM clinical trials
The FDA has released a new draft guidance focused on using minimal residual disease (MRD) and complete response (CR) as primary endpoints in
SOHO Asia 2026
Ambassador Program
News
Video Interviews
Dr. Bor-Sheng Ko discusses the future of SOHO Asia and regional collaborations
Bor-Sheng Ko, MD, PhD, Associate Professor at National Taiwan University College of Medicine and President of the Hematology Society of Taiwan, discusses the